Article Details

Study: Nearly 80% of infants born in 2023-24 RSV season received RSV protection

Retrieved on: 2025-01-08 21:49:25

Tags for this article:

Click the tags to see associated articles and topics

Study: Nearly 80% of infants born in 2023-24 RSV season received RSV protection. View article details on hiswai:

Excerpt

Nirsevimab, a monoclonal antibody, is approved to prevent RSV lower respiratory tract disease (LRTD) in neonates and infants entering, or born during ...

Article found on: www.contemporarypediatrics.com

View Original Article

This article is found inside other hiswai user's workspaces. To start your own collection, sign up for free.

Sign Up
Book a Demo